BR112021026416A2 - Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas - Google Patents

Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas

Info

Publication number
BR112021026416A2
BR112021026416A2 BR112021026416A BR112021026416A BR112021026416A2 BR 112021026416 A2 BR112021026416 A2 BR 112021026416A2 BR 112021026416 A BR112021026416 A BR 112021026416A BR 112021026416 A BR112021026416 A BR 112021026416A BR 112021026416 A2 BR112021026416 A2 BR 112021026416A2
Authority
BR
Brazil
Prior art keywords
regulating
preventing
cell
immune rejection
transplant immune
Prior art date
Application number
BR112021026416A
Other languages
English (en)
Other versions
BR112021026416A8 (pt
Inventor
Zhaohui Liao
Zonghai Li
Original Assignee
Cafa Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cafa Therapeutics Ltd filed Critical Cafa Therapeutics Ltd
Publication of BR112021026416A2 publication Critical patent/BR112021026416A2/pt
Publication of BR112021026416A8 publication Critical patent/BR112021026416A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenasa presente invenção refere-se a uma célula resistente à rejeição imune ao transplante. a célula expressa uma primeira proteína que reconhece uma ou mais células efetoras imunes de um hospedeiro; preferencialmente a célula tem a função de inibir ou eliminar as células efetoras imunes do hospedeiro. a presente invenção também se refere a um método para impedir ou regular a rejeição imune a transplante e um método para impedir ou regular o ataque de células nk em células exógenas.
BR112021026416A 2019-06-28 2020-06-29 Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas BR112021026416A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910576425 2019-06-28
CN201910809425 2019-08-29
CN2020259707 2020-12-30

Publications (2)

Publication Number Publication Date
BR112021026416A2 true BR112021026416A2 (pt) 2022-02-08
BR112021026416A8 BR112021026416A8 (pt) 2022-06-28

Family

ID=74060745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026416A BR112021026416A8 (pt) 2019-06-28 2020-06-29 Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas

Country Status (9)

Country Link
US (1) US20220356447A1 (pt)
EP (1) EP3992204A4 (pt)
KR (1) KR20220028090A (pt)
AU (1) AU2020304139A1 (pt)
BR (1) BR112021026416A8 (pt)
CA (1) CA3144549A1 (pt)
IL (1) IL289353A (pt)
MX (1) MX2021015620A (pt)
WO (1) WO2020259707A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050835A1 (en) * 2017-01-23 2018-07-26 Carsgen Therapeutics Co., Ltd. Bcma-targeting antibody and use thereof
US20210292427A1 (en) * 2018-07-24 2021-09-23 Cafa Therapeutics Limited Method for treating tumor using immune effector cell
WO2023284875A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 嵌合抗原受体
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
WO2024090458A1 (ja) * 2022-10-25 2024-05-02 第一三共株式会社 抑制型ｋｉｒに対するアゴニストを用いた免疫拒絶の回避方法
WO2024140778A1 (zh) * 2022-12-27 2024-07-04 科济生物医药（上海）有限公司 Nkg2d工程化细胞及其组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK3116902T3 (da) * 2014-03-11 2020-04-06 Cellectis Fremgangsmåde til generering af T-celler kompatible for allogen transplantation
EP3445847B1 (en) * 2016-04-20 2024-06-05 Fred Hutchinson Cancer Center Immunomodulatory il2r fusion proteins and uses thereof
CA3050835A1 (en) * 2017-01-23 2018-07-26 Carsgen Therapeutics Co., Ltd. Bcma-targeting antibody and use thereof
JP2020511987A (ja) * 2017-03-28 2020-04-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 移植された組織を拒絶反応から保護するための方法
CN109694854B (zh) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
CN107828730B (zh) * 2017-11-07 2019-04-30 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法
CN107746831B (zh) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Also Published As

Publication number Publication date
EP3992204A1 (en) 2022-05-04
EP3992204A4 (en) 2023-09-27
AU2020304139A1 (en) 2022-02-24
CA3144549A1 (en) 2020-12-30
IL289353A (en) 2022-02-01
KR20220028090A (ko) 2022-03-08
MX2021015620A (es) 2022-04-18
BR112021026416A8 (pt) 2022-06-28
WO2020259707A1 (zh) 2020-12-30
US20220356447A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR112021026416A2 (pt) Célula resistente à rejeição imune a transplante, e, métodos para impedir ou regular rejeição imune a transplante e para impedir ou regular o ataque de célula nk em células exógenas
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
BR112021009717A8 (pt) Método e sistema para fornecimento de recomendações de alocação de recursos humanos multidimensionais
SG11201802373WA (en) Method and device for processing question clustering in automatic question and answering system
GB2560282A (en) Illumination content production and use
MY196175A (en) Chimeric Proteins And Methods Of Regulating Gene Expression
BR112015022852A2 (pt) mecanismos de processamento de vetor que tem configurações de percurso de dados programáveis para proporcionar processamento de vetor de múltiplos modos, e processadores de vetor, sistemas, e métodos, relacionados
WO2017188549A3 (ko) 센텐스 빌드업 영어학습 시스템, 이를 이용한 영어학습 방법 및 그 교습방법
MX2018003490A (es) Traduccion universal.
BR112015031639A2 (pt) integração alvo
MX2020014187A (es) Metodo y sistema para extraccion robotica de recipientes.
BR112018009393A8 (pt) produção microbiana de nicotinamida ribosídeo
BR112017005253A2 (pt) método para produzir biomassa que tem um alto teor de exopolissacarídeo.
ES2721224T3 (es) Composición detergente que comprende una enzima transformadora de ácido oleico
BR112015028457A8 (pt) Composições cosméticas compreendendo óleo de microalgas
BR112018001492A2 (pt) composição para controle de doenças de plantas e método de controle de doenças de plantas
BR112018010499A8 (pt) método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células
AU2018367488A1 (en) Systems and methods for determining microsatellite instability
BR112015001601A2 (pt) células de levedura tendo curso de tca redutor de piruvato em succinato e superexpressão de uma enzima transidrogenase nad(p)+ exógena
WO2019209231A3 (en) System and method for creating recommendation of splitting and merging microservice
WO2021053242A3 (en) Bacteriocins for control of salmonella enterica
BR112022004031A2 (pt) Células doadoras universais
GB2556608A (en) Mitigation of conflicts between content matchers in automated document analysis
AR118524A1 (es) Aparato para rastrear objetos, método de control y programa
BR112017008702A2 (pt) ?mutante de endoxilanase, dna, vetor, célula, método de produção de mutantes de endoxilanase, composição enzimática e método de produção de solução de açúcar?

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CRAGE MEDICAL CO., LIMITED (CN)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]